MA46712A - Combinaisons d'inhibiteurs de fgfr4 et de chélateurs de l'acide biliaire - Google Patents

Combinaisons d'inhibiteurs de fgfr4 et de chélateurs de l'acide biliaire

Info

Publication number
MA46712A
MA46712A MA046712A MA46712A MA46712A MA 46712 A MA46712 A MA 46712A MA 046712 A MA046712 A MA 046712A MA 46712 A MA46712 A MA 46712A MA 46712 A MA46712 A MA 46712A
Authority
MA
Morocco
Prior art keywords
combinations
acid chelators
fgfr4 inhibitors
biliary acid
biliary
Prior art date
Application number
MA046712A
Other languages
English (en)
Inventor
Robin Alec Fairhurst
Porta Diana Graus
Jacqueline Kinyamu-Akunda
Andreas Joerg Mahl
Luigi Manenti
Andreas Weiss
Armin Wolf
Kuno Wuersch
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA46712A publication Critical patent/MA46712A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA046712A 2016-11-02 2017-11-01 Combinaisons d'inhibiteurs de fgfr4 et de chélateurs de l'acide biliaire MA46712A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662416222P 2016-11-02 2016-11-02

Publications (1)

Publication Number Publication Date
MA46712A true MA46712A (fr) 2019-09-11

Family

ID=60661908

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046712A MA46712A (fr) 2016-11-02 2017-11-01 Combinaisons d'inhibiteurs de fgfr4 et de chélateurs de l'acide biliaire

Country Status (17)

Country Link
US (1) US11229643B2 (fr)
EP (1) EP3534902B1 (fr)
JP (2) JP7394623B2 (fr)
KR (1) KR102362648B1 (fr)
CN (2) CN109922804B (fr)
AU (1) AU2017354082B2 (fr)
CA (1) CA3042475C (fr)
ES (1) ES2934341T3 (fr)
IL (1) IL266293B (fr)
MA (1) MA46712A (fr)
MX (1) MX387222B (fr)
PL (1) PL3534902T3 (fr)
PT (1) PT3534902T (fr)
RU (1) RU2742033C2 (fr)
SG (1) SG11201903911UA (fr)
WO (1) WO2018083603A1 (fr)
ZA (1) ZA201902744B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2756748T3 (es) 2014-10-03 2020-04-27 Novartis Ag Uso de derivados de piridilo bicíclicos de anillo fusionado como inhibidores de fgfr4
CN112759593A (zh) * 2019-11-01 2021-05-07 北京伯汇生物技术有限公司 桥环并醛基吡啶衍生物及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5209505B2 (ja) 2006-02-10 2013-06-12 ジェネンテック， インコーポレイテッド 抗ｆｇｆ１９抗体およびその使用方法
EP1918376A1 (fr) 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 favorise la résistance des cellules cancéreuses en réponse aux agents chimiothérapeutiques
WO2008080092A2 (fr) 2006-12-22 2008-07-03 Ironwood Pharmaceuticals, Inc. Méthodes et compositions pour le traitement de troubles oesophagiens
TW201446265A (zh) 2007-04-02 2014-12-16 建南德克公司 克羅梭（ｋｌｏｔｈｏ）ｂｅｔａ調節劑之用途
US8524212B2 (en) 2007-10-24 2013-09-03 Mitsubishi Tanabe Pharma Corporation Prophylactic and/or therapeutic drug for nonalcoholic steatohepatitis
FR2933702A1 (fr) 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
CN102224170A (zh) 2008-09-03 2011-10-19 利琴蒂亚有限公司 抑制与fgfr4相关的癌细胞侵袭的材料和方法
US20100330175A1 (en) 2009-06-24 2010-12-30 Jobdevairakkam Christopher N Cross-linked polyallylamine tablet core
CA2828890A1 (fr) 2011-04-07 2012-10-11 Genentech, Inc. Anticorps anti-fgfr4 et procedes d'utilisation
CN104053449B (zh) * 2011-08-17 2016-12-07 硬木药品公司 胃肠疾患的治疗
NZ703495A (en) 2012-07-11 2018-02-23 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
MX383664B (es) 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
WO2014105849A1 (fr) 2012-12-28 2014-07-03 Xoma (Us) Llc Anticorps spécifiques contre le fgfr4 et méthodes d'utilisation
JP2016520516A (ja) 2013-03-12 2016-07-14 ザ・トランスレーショナル・ジェノミクス・リサーチ・インスティチュート 線維芽細胞増殖因子４に対するハイブリドーマクローンおよびモノクローナル抗体
EP2970317A4 (fr) 2013-03-15 2016-11-02 Dana Farber Cancer Inst Inc Composés pyrimido-diazépinone et procédés de traitement de troubles
TW201605452A (zh) 2013-08-28 2016-02-16 安斯泰來製藥股份有限公司 以嘧啶化合物作爲有效成分之醫藥組成物
SG11201602069WA (en) 2013-10-18 2016-04-28 Eisai R&D Man Co Ltd Pyrimidine fgfr4 inhibitors
CN105683188B (zh) 2013-10-25 2018-02-09 诺华股份有限公司 作为fgfr4抑制剂的稠环二环吡啶基衍生物
WO2015107171A1 (fr) 2014-01-17 2015-07-23 Sanofi Méthodes d'identification de patients souffrant d'un cancer du foie pour lesquels un traitement avec un anticorps anti-fgfr4 antagoniste est plus à même d'être bénéfique
MA38393B1 (fr) 2014-03-13 2018-11-30 Sanofi Sa Composés hétéroaryle et utilisations associées
EP3155005A4 (fr) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Procédés et utilisations pour la modulation de l'homéostasie de l'acide biliaire et le traitement de troubles et maladies de l'acide biliaire
WO2016023894A1 (fr) 2014-08-11 2016-02-18 U3 Pharma Gmbh Anticorps anti-fgfr4 humain
ES2756748T3 (es) 2014-10-03 2020-04-27 Novartis Ag Uso de derivados de piridilo bicíclicos de anillo fusionado como inhibidores de fgfr4
WO2016064960A1 (fr) 2014-10-22 2016-04-28 Incyte Corporation Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CA2976790C (fr) 2015-02-20 2024-02-27 Incyte Corporation Heterocycles bicycliques utilises en tant qu'inhibiteurs de fgfr
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016151501A1 (fr) * 2015-03-25 2016-09-29 Novartis Ag Combinaisons pharmaceutiques
EP3095465A1 (fr) * 2015-05-19 2016-11-23 U3 Pharma GmbH Combinaison d'un inhibiteur de fgfr4 et d'un chélateur d'acides biliaires

Also Published As

Publication number Publication date
WO2018083603A1 (fr) 2018-05-11
MX387222B (es) 2025-03-18
IL266293B (en) 2022-07-01
ES2934341T3 (es) 2023-02-21
EP3534902B1 (fr) 2022-11-23
JP2022033766A (ja) 2022-03-02
AU2017354082B2 (en) 2023-07-27
CA3042475C (fr) 2024-01-16
JP7868965B2 (ja) 2026-06-02
RU2019116061A (ru) 2020-12-04
US20200261444A1 (en) 2020-08-20
PL3534902T3 (pl) 2023-03-27
SG11201903911UA (en) 2019-05-30
AU2017354082A1 (en) 2019-05-23
KR20190082256A (ko) 2019-07-09
ZA201902744B (en) 2021-08-25
CA3042475A1 (fr) 2018-05-11
IL266293A (en) 2019-06-30
EP3534902A1 (fr) 2019-09-11
CN109922804A (zh) 2019-06-21
MX2019005194A (es) 2019-08-05
US11229643B2 (en) 2022-01-25
PT3534902T (pt) 2022-12-07
BR112019008787A2 (pt) 2019-07-16
RU2742033C2 (ru) 2021-02-01
RU2019116061A3 (fr) 2020-12-04
CN109922804B (zh) 2023-11-17
JP2019533701A (ja) 2019-11-21
JP7394623B2 (ja) 2023-12-08
CN117257800A (zh) 2023-12-22
KR102362648B1 (ko) 2022-02-11

Similar Documents

Publication Publication Date Title
EP3454844A4 (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-1
PL3761980T3 (pl) Związki aminokwasowe i sposoby zastosowania
MA41999A (fr) Compositions d'acide obéticholique et procédés d'utilisation
EP3429591A4 (fr) Inhibiteurs substitués de ménine-mll et méthodes d'utilisation
MA49903A (fr) Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
MA46954A (fr) Méthodes de traitement d'états inflammatoires
MA44990A (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-l1
EP3491149A4 (fr) Traitement d'acide nucléique indépendant
EP3630748A4 (fr) Petites molécules inhibitrices d'ire1
EP3373981A4 (fr) Identification et caractérisation de nouvelles molécules d'inhibiteur de corrosion
EP3317273A4 (fr) Inhibiteurs d'egfr et méthodes d'utilisation de ceux-ci
EP3691992A4 (fr) Compositions et procédés d'élimination de métaux lourds de soutions d'acide phosphorique
MA47179A (fr) Composition d'acide dicarboxylique mannuronique
DK3510049T3 (da) Varianter af sur alfa-glucosidase og anvendelser deraf
PL3262183T3 (pl) Test na obecność i wrażliwość bakterii na środki przeciwdrobnoustrojowe
EP3390457A4 (fr) Fabrication de nanocellulose et d'intermédiaires de celle-ci en utilisant de d'acide oxalique dihydraté
HRP20211272T8 (hr) 24-hidroksisteroli supstituirani na poziciji 11 za uporabu u liječenju stanja povezanih sa nmda
EP3402572A4 (fr) Compositions et méthodes de traitement d'états inflammatoires allergiques
DK3710036T3 (da) Stable ascorbic acid compositions and methods of using the same
EP3302588A4 (fr) Compositions et méthodes pour l'adhérence à des surfaces
EP3458079A4 (fr) Compositions et méthodes pour le traitement de l'acné
EP3415146A4 (fr) Inhibiteur de l'activation des inflammasomes
EP3380471A4 (fr) Méthodes et compositions d'inhibition de comt
EP3518995C0 (fr) Composition d'alpha-tcp, de silicate et d'acide aminé phosphorylé
EP3469078A4 (fr) Procédés et compositions d'amplification d'acide nucléique